Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Vaccine being tested on Aberdeen volunteers getting good results

To go with story by Erikka Askeland. Aberdeen will be playing a significant role in the development of a new plant-derived Covid-19 vaccine candidate, Medicago/GSK Picture shows; A volunteer tests Medicago vaccine. unknown. Supplied by Medicago Date; Unknown
To go with story by Erikka Askeland. Aberdeen will be playing a significant role in the development of a new plant-derived Covid-19 vaccine candidate, Medicago/GSK Picture shows; A volunteer tests Medicago vaccine. unknown. Supplied by Medicago Date; Unknown

A Canadian biopharmaceutical company testing a Covid-19 vaccine on volunteers in Aberdeen has hailed the success of its most recent trials.

Medicago, which is developing the drug with UK pharmaceutical giant GlaxoSmithKline (GSK), revealed the treatment triggered protective antibody levels 10 times higher than in patients recovering from Covid-19 in second stage trials which completed last month.

It also highlighted there were no “related severe adverse events” reported in the phase two trials of the drug, with any temporary side effects reported as mild and short-lived.

Last month, plans to recruit 1,500 volunteers across the UK for the larger phase three trials of the vaccine were announced, with Aberdeen playing a significant role. This was part of a wider global test involving 30,000 subjects in North America, Latin America and Europe designed to evaluate the efficacy and safety of the drug compared to a placebo.

NHS Grampian has confirmed 145 people in Aberdeen have been recruited to be involved with the next phase of testing.

The Medicago vaccine candidate against Covid-19 is thought to be the first “plant-based” treatment against the virus.

Uniquely it uses plants as bioreactors –  or mini-factories –  that hijack the plant’s own biology  to produce the key biological products of the vaccine, known as “virus-like particles”. GSK has added an adjuvant, a substance used to increase the efficacy or potency of the drug.

Medicago greenhouse.

The particles developed by the Canadian company are derived from “nicotiana benthamiana”, a close relative of tobacco, which it grows in a bio- secure greenhouse. The Canadian firm is part-funded by the cigarette and tobacco manufacturing company, Philip Morris International (PMI), which recently confirmed plans to become a “majority smoke-free business” by 2025.

The vaccine can be stored in refrigerators which means it can be distributed widely and easily.

The drug has been fast tracked for testing by US Food and Drug Administration (FDA) while the UK trial is supported by the National Institute for Health Research (NIHR), NHS Research Scotland (NRS) and Health and Care Research Wales.

The UK authority, the Medicines & Healthcare products Regulatory Agency (MHRA) will rule if it can be used to deployed in the UK as a vaccine once trials are complete.

Nathalie Landry, executive vice president, scientific and medical affairs at Medicago said: “These results give us confidence as we continue to move forward with our Phase 3 clinical trial. We hope to add another tool in the global fight against COVID-19, particularly as cross-protection emerges as an important consideration in vaccination efforts worldwide.”

Thomas Breuer, chief medical officer, GSK Vaccines said, “We are delighted to see that the results suggest a very strong immune response, Medicago’s COVID-19 vaccine candidate combined with GSK’s pandemic adjuvant was also well tolerated, reinforcing its potential benefits. We now look forward to the outcome of the ongoing Phase 3 trial of this refrigerator-stable vaccine candidate as the next step forward in our contribution to the global response to the pandemic.”